Drug Profile
Charis 1000
Alternative Names: C 1K; Charis1000Latest Information Update: 02 Sep 2023
Price :
$50
*
At a glance
- Originator Ensol Biosciences
- Class Antineoplastics; Peptides
- Mechanism of Action Phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Triple negative breast cancer
Most Recent Events
- 28 Jun 2023 Ensol Bioscience completes a phase I clinical trials in Triple negative Breast cancer (In Volunteers) in South Korea (SC) (Ensol Biosciences pipeline, March 2022) (NCT05701644)
- 02 Jan 2023 Phase-I clinical trials in Triple negative Breast cancer (In Volunteers) in South Korea (SC) (Ensol Biosciences pipeline, March 2022) (NCT05701644)
- 19 Jul 2018 Preclinical trials in Triple negative Breast cancer in South Korea (Ensol Biosciences pipeline, July 2018)